http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007141046-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_08bb03badfcbe29bd17e02ef50a9e870 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d1b174da24b0ff2e1fa83412127905f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c887d684c265ec67a66eb190dfc3ed48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a2bcaf91101a370a3d64e3190366357f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2007-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_059ae6a7fe1af124a67ccfe2330e7f60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9feb7a779ab157603593beea018e2ed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fb872a3cc64d9ce0ab02858601ba1b1 |
| publicationDate | 2008-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2007141046-B1 |
| titleOfInvention | Method for identifying genetic markers for secondary tumors and means for the identification, labelling and targeting of secondary tumors |
| abstract | In comparison with primary tumors, where the organ by itself is the starting point of the malignant degeneration, metastases inherit a different emergence. The molecular causes leading to secondary liver malignancies are unknown so far. The aim of the present invention is therefore to make available an easy and efficient method for identifying therapeutical targets in secondary tumors, the use of novel therapeutical targets identified by the method for screening and determiningbeneficial means and/or drugs, and means and drugs for identifying, labeling and treating secondary metastases in the liver made up of or derived from tumor cells of the colon. In principle, expression of transcription factors is studied in the primary tumor, the secondary tumor and in the healthy organ, wherein the secondary tumor is formed, according to the invention, in particular of transcription factors being enriched in the healthy tissue of the organ, wherein the secondary tumor is formed, e.g. expression of liver enriched transcription factors HNF6 and/or Foxa2 or of NGN3, HSP105B, HSP10, HNF1 β, C/EBP is studied, such as by reverse transcription polymerase chain reaction, by gene chip analysis, by Western blotting technique, by studying the DNA binding of liver enriched transcription factors by electromobility shift assay (EMSA) or by genomic sequencing of therapeutical targets, such as of HNF6. |
| priorityDate | 2006-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.